DK1501848T3 - Syntese af låst nukleinsyrederivater - Google Patents

Syntese af låst nukleinsyrederivater

Info

Publication number
DK1501848T3
DK1501848T3 DK03718663T DK03718663T DK1501848T3 DK 1501848 T3 DK1501848 T3 DK 1501848T3 DK 03718663 T DK03718663 T DK 03718663T DK 03718663 T DK03718663 T DK 03718663T DK 1501848 T3 DK1501848 T3 DK 1501848T3
Authority
DK
Denmark
Prior art keywords
lna
synthesis
nucleic acid
acid derivatives
locked nucleic
Prior art date
Application number
DK03718663T
Other languages
Danish (da)
English (en)
Inventor
Mads Detlef Sorensen
Jesper Wengel
Troels Koch
Signe M Christensen
Christoph Rosenbohm
Daniel Sejer Darwin C Pedersen
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Application granted granted Critical
Publication of DK1501848T3 publication Critical patent/DK1501848T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK03718663T 2002-05-08 2003-05-08 Syntese af låst nukleinsyrederivater DK1501848T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200712 2002-05-08
DKPA200201214 2002-08-16
PCT/DK2003/000305 WO2003095467A1 (en) 2002-05-08 2003-05-08 Synthesis of locked nucleic acid derivatives

Publications (1)

Publication Number Publication Date
DK1501848T3 true DK1501848T3 (da) 2007-10-22

Family

ID=29421786

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03718663T DK1501848T3 (da) 2002-05-08 2003-05-08 Syntese af låst nukleinsyrederivater

Country Status (9)

Country Link
EP (1) EP1501848B1 (ja)
JP (1) JP4476802B2 (ja)
AT (1) ATE369375T1 (ja)
AU (1) AU2003222743B2 (ja)
CA (1) CA2484526C (ja)
DE (1) DE60315444T2 (ja)
DK (1) DK1501848T3 (ja)
ES (1) ES2290448T3 (ja)
WO (1) WO2003095467A1 (ja)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
HUE037352T2 (hu) 2002-04-05 2018-08-28 Roche Innovation Ct Copenhagen As A HIF-1alfa expresszálódását módosító oligomer vegyületek
DK2284269T3 (en) 2002-11-18 2017-10-23 Roche Innovation Ct Copenhagen As Antisense design
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
DE602004023279D1 (de) 2003-03-21 2009-11-05 Santaris Pharma As Analoga kurzer interferierender rna (sirna)
RU2377301C2 (ru) 2003-12-23 2009-12-27 Сантарис Фарма А/С ОЛИГОМЕРНОЕ СОЕДИНЕНИЕ, ПОНИЖАЮЩЕЕ ЭКСПРЕССИЮ ЧЕЛОВЕЧЕСКОГО ГЕНА Bcl-2, КОНЪЮГАТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ОЛИГОМЕРНОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА
EP1824975B9 (en) 2004-11-09 2011-04-20 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
CA2587173C (en) 2004-11-09 2016-09-06 Santaris Pharma A/S Potent lna oligonucleotides for the inhibition of hif-1a expression
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
AU2007229161B2 (en) 2006-03-23 2012-07-12 Roche Innovation Center Copenhagen A/S Small internally segmented interfering RNA
CN102851291B (zh) 2006-04-03 2016-03-09 斯特拉有限责任公司 包含抗微小rna反义寡核苷酸的药物组合物
KR101407707B1 (ko) 2006-04-03 2014-06-19 산타리스 팔마 에이/에스 Ａｎｔｉ-ｍｉｒｎａ 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물
EP2054415A1 (en) * 2006-07-14 2009-05-06 Santaris Pharma A/S Adenosine receptor antagonists
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
EP2126079A1 (en) 2007-03-22 2009-12-02 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
EP2173373B1 (en) 2007-06-06 2020-04-15 Sarepta Therapeutics, Inc. Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
EP2183360B1 (en) 2007-08-30 2017-01-11 Hadasit Medical Research Services&Development Company Ltd. Nucleic acid sequences comprising nf-(kappa)b binding site within o(6)-methylguanine-dna-methyltransferase (mgmt) promoter region and uses thereof for the treatment of cancer and immune-related disorders
WO2009039173A2 (en) 2007-09-19 2009-03-26 Applied Biosystems Inc. SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF
CN101821391B (zh) 2007-10-04 2016-04-27 桑塔里斯制药公司 微小聚体
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
EP2421970B1 (en) 2009-04-24 2016-09-07 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
EP2456870A1 (en) 2009-07-21 2012-05-30 Santaris Pharma A/S Antisense oligomers targeting pcsk9
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
EP2542678B1 (en) 2010-03-04 2017-04-12 InteRNA Technologies B.V. A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT
NZ704322A (en) 2010-07-06 2016-07-29 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
CN107266597A (zh) * 2011-07-21 2017-10-20 罗地亚运作公司 瓜耳胶羟丙基三甲基氯化铵及其在发用处理组合物中的用途
US9073960B2 (en) 2011-12-22 2015-07-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
ES2886147T3 (es) 2011-12-22 2021-12-16 Interna Tech B V MiARN para el tratamiento del cáncer de cabeza y de cuello
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10201556B2 (en) 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
EP2943570B1 (en) 2013-01-14 2018-01-03 Pierfrancesco Tassone Inhibitors of mirnas 221 and 222 for anti-tumor activity in multiple myeloma
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
SG10201908122XA (en) 2013-06-27 2019-10-30 Roche Innovation Ct Copenhagen As Antisense oligomers and conjugates targeting pcsk9
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
AU2016217825B2 (en) 2015-02-15 2022-03-10 Arcturus Therapeutics, Inc. Acyl-amino-LNA and/or hydrocarbyl-amino-LNA oligonucleotides
TW201718618A (zh) * 2015-09-18 2017-06-01 田邊三菱製藥股份有限公司 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物
IL308174A (en) 2015-10-09 2024-01-01 Univ Southampton Gene expression modulation and dysregulated protein expression scanning
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
EP3390636B1 (en) 2015-12-14 2021-05-19 Cold Spring Harbor Laboratory Antisense oligomers for treatment of dravet syndrome
WO2017188898A1 (en) 2016-04-29 2017-11-02 Nanyang Technological University G-quadruplex-containing antisense oligonucleotides
WO2018024849A1 (en) 2016-08-03 2018-02-08 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
GB2599884B (en) 2017-08-25 2022-08-31 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
EP3704250A1 (en) 2017-11-03 2020-09-09 InteRNA Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
WO2019155094A1 (en) 2018-02-12 2019-08-15 Interna Technologies B.V. Anticancer microrna and lipid formulations thereof
JP2021523227A (ja) 2018-05-04 2021-09-02 ストーク セラピューティクス，インク． コレステリルエステル蓄積症の処置のための方法及び組成物
IT201900017234A1 (it) 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
KR20230022409A (ko) 2020-05-11 2023-02-15 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머
KR20230144588A (ko) 2021-02-12 2023-10-16 머랜드 파마슈티칼스, 인크. 저산소증 및 허혈-관련 장애의 치료를 위한 작용제, 조성물 및 방법
KR20230170690A (ko) 2021-03-26 2023-12-19 뉴미르나 테라퓨틱스 에이피에스 MicroRNA-134 억제제들
EP4313074A1 (en) 2021-03-26 2024-02-07 Neumirna Therapeutics ApS Microrna-27b inhibitors
WO2022254021A1 (en) 2021-06-04 2022-12-08 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
EP4389892A1 (en) 2021-08-17 2024-06-26 Korea Advanced Institute of Science and Technology Antisense oligonucleotide targeting cav3.1 gene and uses thereof
AU2022329462A1 (en) 2021-08-19 2024-03-28 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
EP4332239A1 (en) 2022-08-30 2024-03-06 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2283298T3 (es) * 1999-05-04 2007-11-01 Santaris Pharma A/S Analogos de l-ribo-lna.
DK1334109T3 (da) * 2000-10-04 2006-10-09 Santaris Pharma As Forbedret syntese af purin-blokerede nukleinsyre-analoger

Also Published As

Publication number Publication date
ES2290448T3 (es) 2008-02-16
AU2003222743B2 (en) 2008-12-11
WO2003095467A1 (en) 2003-11-20
EP1501848B1 (en) 2007-08-08
CA2484526A1 (en) 2003-11-20
AU2003222743A1 (en) 2003-11-11
ATE369375T1 (de) 2007-08-15
CA2484526C (en) 2009-10-13
EP1501848A1 (en) 2005-02-02
DE60315444D1 (en) 2007-09-20
JP4476802B2 (ja) 2010-06-09
DE60315444T2 (de) 2008-04-30
JP2005532319A (ja) 2005-10-27

Similar Documents

Publication Publication Date Title
DK1501848T3 (da) Syntese af låst nukleinsyrederivater
TW200503724A (en) Novel pharmaceuticals
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
IL172015A0 (en) Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
WO2008141248A3 (en) Thiocarbon-protecting groups for rna synthesis
BRPI0516911A (pt) método para a preparação de um composto e composto de anilina
MY161575A (en) Mixture for the treatment of urea-containing fertilizers
BRPI0411268B8 (pt) processo para a preparação de compostos 3-aril butil-amina substituído
GB0521508D0 (en) Organic compounds
TW200640912A (en) Novel processes for the preparation of a 2H-chromene
GEP20125512B (en) Process for synthesis of agomelatin
BRPI0816911A8 (pt) Processo para preparação de 4-aminobut-2-enolidas
WO2009137455A3 (en) Cure accelerators for anaerobic curable compositions
IL208290A0 (en) Process for the preparation of 10-deacetyl-bis-7, 10- trichloroacetylbaccatin iii
WO2007049295A3 (en) An improved one pot process for making key intermediate for gemcitabine hcl
DK1877370T3 (da) Fremgangsmåde til fremstilling af hydrazon-derivater
WO2011038152A3 (en) Toll-like receptor modulators and uses thereof
WO2004002990A3 (en) Synthesis of purine derivatives
GB0327323D0 (en) Novel pharmaceuticals
WO2006043175A3 (en) Process for preparing purine compounds
WO2007080470A3 (en) A method for the purification of levetiracetam
EP1127873A3 (en) Process for preparing substituted Benzoyl Cyanide Amidinohydrazones
WO2011161255A3 (en) Processes for the resolution of nitrogen substituted (s) - 5 -alkoxy- 2 -aminotetralin derivatives
IL183805A0 (en) Process for preparing substituted thiophenesulfonyl isocyanates
MX2009013336A (es) Sintesis de 3-aminopirazoles sustituidos.